Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

This study is testing a three-drug combination — immunotherapy (a PD-1 inhibitor), hormone therapy (an aromatase inhibitor), and a targeted drug that blocks a growth pathway (an AKT inhibitor) — for premenopausal women with hormone receptor-positive advanced breast cancer that has stopped responding to standard hormone-blocking treatments. **You may be eligible if...** - You are a premenopausal or perimenopausal woman over 20 years old - You have confirmed hormone receptor-positive (ER+) advanced or metastatic breast cancer - Your cancer has become resistant to at least one hormonal treatment (either relapsed during adjuvant therapy or within 2 lines of therapy for advanced disease) - You have not received chemotherapy for your advanced disease - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You are postmenopausal - You have received prior chemotherapy for advanced or metastatic disease - You are pregnant or breastfeeding - Your tumor does not have the hormone receptor positivity profile required Talk to your doctor to see if this trial is right for you.